Skip to main content
. 2021 Apr 1;42(13):1228–1230. doi: 10.1093/eurheartj/ehab092

Graphical Abstract.

Graphical Abstract

Effect of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) or heart failure with reduced ejection fraction (HFrEF). CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HF, heart failure. *Data from DAPA-CKD5  ,  6. #Data from a meta-analysis from DAPA-HF and EMPEROR-Reduced.8